FDA Enforcement Class II Terminated

LIAISON 1-84 PTH Assay - Product Usage: is an in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of parathyroid hormone (1-84) in human serum and EDTA plasma. Measurements of parathyroid hormone levels are used in the differential diagnosis of hypercalcemia and hypocalcemia resulting from disorders of calcium metabolism. The test has to be performed on the LIAISON¿ Analyzer family.

Recall: Z-1342-2021 · Reported April 7, 2021

Enforcement

Recall Number
Z-1342-2021
Event ID
87501
Classification
Class II
Status
Terminated
Product Type
Devices
Firm
Diasorin Inc.
Voluntary / Mandated
Voluntary: Firm initiated
Initial Notification
E-Mail
Report Date
April 7, 2021
Initiation Date
November 23, 2020
Classification Date
April 1, 2021
Termination Date
July 6, 2023
Address
1951 Northwestern Ave S, Stillwater, MN, 55082-7536, United States

Description

LIAISON 1-84 PTH Assay - Product Usage: is an in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of parathyroid hormone (1-84) in human serum and EDTA plasma. Measurements of parathyroid hormone levels are used in the differential diagnosis of hypercalcemia and hypocalcemia resulting from disorders of calcium metabolism. The test has to be performed on the LIAISON¿ Analyzer family.

Reason

Potential for system to produce falsely elevated parathyroid hormone (PTH) results from patient samples.

Code Info

REF 310630; lot numbers: 134909, 134909A and 134909B; UDI: 08056771600125

Distribution

Worldwide distribution - US Nationwide in the states of KY, OH, GA, PA, FL and the countries of Canada, Argentina, Bahrain, Bosnia & Herzegovnia, Iraq, Jordan, Morocco, Nepal, Russia, Serbia, Singapore, Taiwan, Thailand, Tunisia, Dubai, Italy, Israel, Brazil, Mexico, Australia, and Bulgaria.

Quantity

5,895 devices